NCT02933762View on ClinicalTrials.gov

A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions

Healthy

Interventions

DRUG

JNJ-54175446

Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.

DRUG

Placebo

Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.

Trial Locations (1)

Unknown

Merksem

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02933762 - A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma | Biotech Hunter | Biotech Hunter